Short answer · Medically reviewed summary · Last updated: 2023-07-13
Fetal Hydantoin Syndrome (FHS) is a condition that occurs in babies whose mothers took the medication phenytoin (Dilantin) during pregnancy to manage epilepsy or other seizure disorders. The prevalence of FHS is relatively low, affecting an estimated 1 to 2 per 1,000 live births.
What is the prevalence of Fetal Hydantoin Syndrome?
Prevalence of Fetal Hydantoin Syndrome: how many people are affected worldwide, differences by sex and region, with sources.
Fetal Hydantoin Syndrome (FHS) is a condition that occurs in babies whose mothers took the medication phenytoin (Dilantin) during pregnancy to manage epilepsy or other seizure disorders. The prevalence of FHS is relatively low, affecting an estimated 1 to 2 per 1,000 live births. While this may seem like a small number, it is important to note that the impact on affected individuals can be significant.
FHS can lead to a range of physical and developmental abnormalities, including distinctive facial features, growth deficiencies, intellectual disabilities, and delays in motor skills. The severity of symptoms can vary widely among affected individuals, with some experiencing milder effects while others may face more significant challenges.
It is crucial for healthcare providers to be aware of a pregnant woman's medication history and potential risks associated with certain drugs, including phenytoin. Close monitoring and appropriate management can help minimize the risk of FHS and ensure the best possible outcomes for both mother and baby.
